Future cardiovascular diseases in women with gestation hypertension Circulatory System
Conditions
Interventions
This is a cross-sectional study of women with a history of normal and hypertensive pregnancies. The researchers propose to examine:
1. Long-term (0.5-5 years) postnatal cardiovascular changes in women
Sponsors
University of Dundee
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Case group: Women who: 1. Are aged 18 years or above 2. Are able to give written informed consent (ICF) 3. Have given birth in the last 6-60 months 4. Were diagnosed with gestational hypertension (systolic BP= 140 mmHg or diastolic BP =90 mmHg) in their last pregnancy. Control group: Women who are: 1. Aged 18 years or above 2. Able to give written informed consent (ICF) 3. Have no history of gestational hypertension
Exclusion criteria
Exclusion criteria: Exclusion criteria are the same for both case and control groups: Case group: 1. Women with ophthalmic disorders 2. Women who had hypertension prior to pregnancy 3. Maternal age less than 18 years at delivery. 4. Women who are not capable of giving informed consent (ICF). 5. Individuals participating in the clinical phase of another interventional trial/study or have done so within the last 30 days (unless they are participating in the follow-up phase of another interventional trial/study, or who are enrolled in an observational study, will be co-enrolled where the CIs of each study agree) Control group: 1. Women with any history of gestational hypertension (systolic BP = 140 mmHg or diastolic BP = 90 mmHg)) 2. Women with ophthalmic disorders 3. Women who had hypertension prior to pregnancy 4. Maternal age less than 18 years at delivery. 5. Women who are not capable of giving informed consent (ICF). 6. Individuals participating in the clinical phase of another interventional trial/study or have done so within the last 30 days (unless they are participating in the follow-up phase of another interventional trial/study, or who are enrolled in an observational study, will be co-enrolled where the CIs of each study agree)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Retinal vascular health measured using retinal imaging (Canon camera) (VAMPIRE: Vascular Assessment and Measurement Platform for Images of the REtina) 2. Endothelial function measured using retinal imaging and ultrasound pulse-wave Doppler 3. Cardiovascular function biomarkers measured using blood biomarker analysis (sFlt-1 & PLGF, endothelin-1) Measured at a single timepoint per participant (6 to 60 months postpartum) | — |
Secondary
| Measure | Time frame |
|---|---|
| Long-term cardiovascular risk indicators measured using cardiovascular risk assessment tools (e.g., blood pressure, etc) at a single timepoint per participant (6 to 60 months postpartum) | — |
Countries
Scotland, United Kingdom
Contacts
Public ContactSarah Alkhurainej
Outcome results
None listed